Zealand Pharma reports higher costs in 2021

While Zealand Pharma’s costs went up last year, the company expects spending in 2022 to reach around the same level as the two financial periods preceding 2021.

Photo: Zealand Pharma / PR

On Thursday, Zealand Pharma publicized its annual report for 2021, showcasing lower sales and greater costs compared to the preceding year.

The company had a 2021 revenue of USD 44.6m, which is down from 2020’s USD 54.2m.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs